Cart
sales@molnova.com
NCD-25
CAS No. 1456972-46-5
NCD-25( NCD25 | NCD 25 )
Catalog No. M11975 CAS No. 1456972-46-5
NCD-25 is a novel potent, selective LSD1 inhibitor with IC50 of 0.48 uM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameNCD-25
-
NoteResearch use only, not for human use.
-
Brief DescriptionNCD-25 is a novel potent, selective LSD1 inhibitor with IC50 of 0.48 uM.
-
DescriptionNCD-25 is a novel potent, selective LSD1 inhibitor with IC50 of 0.48 uM, exerts highly selective inhibitory activity on LSD1 but no other enzymes, such as MAO.
-
In Vitro——
-
In Vivo——
-
SynonymsNCD25 | NCD 25
-
PathwayChromatin/Epigenetic
-
TargetHistone Demethylase
-
RecptorHistone Demethylase
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1456972-46-5
-
Formula Weight531.7
-
Molecular FormulaC35H37N3O2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical NameN-((2S)-1-(benzylamino)-1-oxo-6-((2-phenylcyclopropyl)amino)hexan-2-yl)-[1,1'-biphenyl]-4-carboxamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Miyamura S, et al. Org Biomol Chem. 2016 Sep 28;14(36):8576-85.
2. Sugino N, et al. Leukemia. 2017 Nov;31(11):2303-2314.
3. Ogasawara D, et al. Angew Chem Int Ed Engl. 2013 Aug 12;52(33):8620-4.
molnova catalog
related products
-
GSK-LSD1 dihydrochlo...
GSK-LSD1 2HCl is a specificity irreversible LSD1 inhibitor (IC50: 16 nM). The selectivity of GSK-LSD1 for LSD1 is >1000 fold over other closely related FAD utilizing enzymes (i.e. MAO-A, LSD2, MAO-B).
-
P3FI-63
P3FI-63 is a selective KDM3B inhibitor (IC50: 7 μM) with antitumor activity for the study of fusion-positive rhabdomyosarcoma and other transcriptionally addictive cancers.
-
ORY-1001 trans and c...
ORY-1001 (RG-6016) is a highly potent, selective inhibitor of lysine-specific demethylase KDM1A (LSD1) with IC50 of 18 nM.
